26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2021-09, Vol.85 (3), p.AB86-AB86
Main Authors: Papp, Kim A., Lebwohl, Mark G., Puig, Lluís, Zeng, Jiewei, Rubant, Simone, Sinvhal, Ranjeeta, Zhao, Yiwei, Alperovich, Gabriela, Leonardi, Craig
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2021.06.370